Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | PREP | P48147 | 1/20 | 0.43 |
| ▸ | FAP | Q12884 | 1/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2544615 | 0.69 | CHRNA3 (0.68) | SLC6A4SLC6A2CHRNB4CHRNA3 | |
| SCHEMBL1396836 | 0.69 | CHRNA3 (0.68) | SLC6A4SLC6A2CHRNB4CHRNA3 | |
| SCHEMBL10550803 | 0.67 | GRM2 (0.38) | DPP4PREPFAPDPP8DPP9 | |
| SCHEMBL1903030 | 0.66 | TSHR (0.51) | SLC6A4LMNA | |
| SCHEMBL30216492 | 0.66 | TSHR (0.51) | SLC6A4LMNA | |
| SCHEMBL22265724 | 0.65 | SLC6A2 (0.53) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2302832 | 0.64 | SSTR4 (0.48) | SLC6A4SLC6A2SLC6A3GRM2 | |
| Hydrochloric Acid SCHEMBL1475217 | 0.64 | SLC6A2 (0.51) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL1397024 | 0.64 | SLC6A4 (0.40) | DPP4PREPFAPDPP8DPP9 | |
| SCHEMBL2202363 | 0.64 | SSTR4 (0.40) | DPP4PREPFAPDPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1912994-B1 | ADENINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-03-12 | — | — | EP | disclosed |
| US-7977343-B2 | Adenine derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-07-12 | — | — | US | disclosed |
| US-20100160352-A1 | ADENINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2010-06-24 | — | — | US | disclosed |
| EP-1912994-A1 | ADENINE DERIVATIVES | Merck Patent GmbH (DE) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007017069-A1 | ADENINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160352-A1 | ADENINE DERIVATIVES | HSP90AA1, TRAP1, HSP90AB1 | DPP4 4398/4885PREP 3153/4885FAP 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.